Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Sonographic skin features and shear wave elastography in distinguishing active from inactive morphea lesions: A case-control study.
J Am Acad Dermatol
January 2025
Department of Dermatology, Universidad de Chile, Santiago, Chile.
The causal effects of inflammatory and autoimmune skin diseases on thyroid diseases: evidence from Mendelian randomization study.
Front Endocrinol (Lausanne)
September 2024
Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China.
Article Synopsis
- The study used two-sample Mendelian randomization (MR) to investigate the links between inflammatory or autoimmune skin diseases and thyroid diseases.
- Genetic data was analyzed from a large sample of participants with various skin conditions and thyroid disorders to assess risks.
- Key findings indicated that atopic dermatitis (AD), systemic lupus erythematosus (SLE), and seborrheic dermatitis (SD) significantly increase the risk of hypothyroidism, while bullous pemphigoid (BP) lowers that risk; no causal effects were found for hyperthyroidism.
A Case of Scleroderma With Coexisting Multiple Myeloma and Bullous Pemphigoid.
Cureus
August 2024
Hematology, Maltepe University Faculty of Medicine, Istanbul, TUR.
An 83-year-old female patient presented to our nephrology outpatient clinic with complaints of weakness, edema, abdominal pain, and constipation, with a preliminary diagnosis of chronic kidney failure related to heart failure. The patient had undergone mitral valve replacement surgery 10 years prior and was diagnosed with chronic renal failure six years prior. Laboratory tests revealed mild normochromic normocytic anemia, consistently high erythrocyte sedimentation rate (ESR) above 100 mm/h, and nephrotic-range proteinuria, prompting suspicion of multiple myeloma.
View Article and Find Full Text PDF[Bullous morphea: A rare form of localized scleroderma].
Ann Pathol
August 2024
Faculté de médecine et de pharmacie, université Mohammed V de Rabat, 10000 Rabat, Maroc.
Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments.
Adv Rheumatol
August 2024
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- BTK, or Bruton's tyrosine kinase, is crucial for transmitting signals in cells, especially B and T immune cells, affecting their growth and survival.
- Various BTK inhibitors are being researched for treating immune disorders and blood cancers, with ongoing clinical trials exploring their effectiveness.
- The article reviews how these inhibitors work, discusses recent findings in autoimmune and inflammatory diseases, and addresses potential side effects and patient risks associated with their use.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!